Equity · Healthcare
Pfizer Inc. (PFE) perpetual futures
PFE perpetual futures on 15 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade PFEUSDT.
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines for diverse therapeutic areas, including COVID-19 treatments like Paxlovid and vaccines like Comirnaty.
Price chart
Use the left and right arrow keys to inspect points on the chart.
Trading data
Perpetual market activity
15/15 live markets
Trading data
Perpetual market activity
Spot performance
Venue matrix
15 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
| Trade | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ourbit | Trade | PFE/USDT | Trading | $27.47 | 0.0% APR 0.000% every 8h | +7.3 bps | $160.5K | $1.8M | $187.5K | USDT | 20x | |
XT.com | Trade | PFE/USDT | Trading | $27.48 | 0.0% APR 0.000% every 8h | +7.3 bps | $31.6K | $263K | - | USDT | 20x | |
KuCoin | Trade | PFE/USDT | Trading | $27.49 | 0.0% APR 0.000% every 8h | +30.2 bps | $3.7K | $241.5K | $5.3K | USDT | 20x | |
Binance | Trade | PFE/USDT | Trading | $27.48 | 0.0% APR 0.000% every 8h | +7.3 bps | $52.8K | $175.3K | $115.9K | USDT | - | |
BingX | Trade | PFE-USDT | Trading | $27.61 | -5.5% APR -0.00500% every 8h | +10.9 bps | $53.8K | $144.8K | $758.4 | USDT | - | |
Variational | Trade | PFE/USDC | Trading | $27.43 | 0.0% APR 0.000% every 8h | +14.3 bps | no public depth feed | $127.5K | $5.1K | USDC | - | |
MEXC | Trade | PFE/USDT | Trading | $27.47 | 0.0% APR 0.000% every 8h | +7.3 bps | $55.4K14 min | $101.6K | $21.6K | USDT | 20x | |
Bitunix | Trade | PFE/USDT | Trading | $27.48 | -1.9% APR -0.00177% every 8h | +14.6 bps | $49.1K | $74.1K | $20.8K | USDT | 20x | |
HTX | Trade | PFE/USDT | Trading | $27.48 | 0.0% APR 0.000% every 8h | +97.7 bps | $7K | $30.4K | $6K | USDT | - | |
Bitget | Trade | PFE/USDT | Trading | $27.49 | 0.0% APR 0.000% every 8h | +0.4 bps | $444.5K | $20.9K | $159.8K | USDT | 20x | |
OKX | Trade | PFE/USDT | Trading | $27.52 | 0.0% APR 0.000% every 8h | +12.7 bps | $8.5K | $5.3K | $64K | USDT | 20x | |
Bybit | Trade | PFE/USDT | Trading | $27.42 | 0.0% APR 0.000% every 8h | +18.2 bps | $8.7K | $437.6 | $63.7K | USDT | 25x | |
Helix (Injective) | Trade | PFE/USDC | Trading | $27.44 | -24.1% APR -0.00275% every 1h | - | $0 | $343.5 | - | USDC | 12x | |
Gate.io | Trade | PFE/USDT | Trading | $27.48 | 0.0% APR 0.000% every 8h | +40.0 bps | $22.1K | $49 | $29.4K | USDT | 20x | |
LBank | Trade | PFE/USDT | Trading | $27.48 | 0.0% APR 0.000% every 8h | +7.3 bps | $368.4K | $618.6K | - | USDT | 20x |
Tokenized wrappers of the real stock, tradable on-chain and on crypto exchanges around the clock. Premium/discount compares the token price to our stock reference price. Data: CoinMarketCap · Robinhood · DexScreener · GeckoTerminal.
| Product | Price | Premium vs stock | 24h Vol. | Market Cap | Chains |
|---|---|---|---|---|---|
| PFEXxStocks | $27.27 | -0.83% | $320k | $336k | Solana · Arbitrum · BNB Smart Chain (BEP20) · TON |
| PFERobinhood | $27.53 | -0.87% | $119 | $176k | Robinhood Chain |
| PFEonOndo GM | $29.40 | +6.94% | – | $49k | Ethereum · BNB Smart Chain (BEP20) · Solana |
| Exchange | Pair | Price | 24h Vol. | Liquidity |
|---|---|---|---|---|
uniswapDEX · robinhood | PFE/CRCL ↗ | $27.53 | $119 | $13k |
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kBroad liquidity · 10 of 15 venues absorb $10k · Typical cost: +21.8 bps – +44.6 bps
Too thin: OKX, HTX, KuCoin
No fresh book data: Variational, Helix (Injective)
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
PFETightest spread
PFEHighest volume
PFEFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketNext catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsRevenue mix
Latest annualAnalysts
Price targets in USD| Consensus rating | Hold |
|---|---|
| Average 12-month price target | $31.50 |
| 12-month target range (low – high) | $27 – $40 |
| Ratings in the provider's consensus | 40 |
Price targets as of 2026-11-22
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 1 | 8 | 17 | 1 | 1 |
| Oct 2026 | 2 | 8 | 17 | 1 | 1 |
| Sep 2026 | 2 | 8 | 16 | 1 | 1 |
| Aug 2026 | 2 | 8 | 16 | 1 | 1 |
| Jul 2026 | 2 | 9 | 16 | 1 | 1 |
| Jun 2026 | 2 | 9 | 16 | 1 | 2 |
| May 2026 | 2 | 9 | 15 | 1 | 2 |
| Apr 2026 | 2 | 9 | 15 | 1 | 2 |
| Mar 2026 | 2 | 8 | 16 | 1 | 2 |
| Feb 2026 | 3 | 7 | 16 | 1 | 2 |
| Jan 2026 | 3 | 7 | 15 | 1 | 0 |
| Dec 2025 | 3 | 7 | 15 | 1 | 0 |
Ownership
Institutional · 2026-Q3Reference market activity
PFE-PERPPrice performance
11Insider activity
FY2026 Q4Insider transactions
25Pfizer CEO Albert Bourla received an award of 21 Phantom Stock Units SSP at $0.00, bringing his reported holdings to 795,823 units.
Pfizer CEO Albert Bourla received an award of 20 Phantom Stock Units SSP at $0.00 on Oct 30, 2026, as reported in a Form 4 filing. He held 783,828 units afterward.
Pfizer CEO Albert Bourla received an award of 20 phantom stock units (SSP) on 2026-10-15, at $0.00, bringing his reported holdings to 783,997 units. Form 4 filed 2026-10-16.
Pfizer director and Chairman & CEO Albert Bourla received an award of 71 Phantom Stock Units SSP on 2026-10-13, a grant of compensation, bringing reported holdings to 783,981.
Pfizer CEO Albert Bourla reported a Form 4 award of 21 Phantom Stock Units (SSP) at $0.00, an A-Award grant, bringing his reported holdings to 783,888 units.
Director Buckley Mortimer J received an award of 1,308 Phantom Stock Units in Pfizer Inc. on 2026-09-25, at $0.00 per share, bringing holdings to 28,040 units.
Pfizer director Joseph Echevarria received an award of 1,613 phantom stock units at $0.00 on 2026-09-25, bringing his holdings to 169,739 units. This is compensation, not an open-market purchase.
Pfizer Inc. director Shantanu Narayen received an award of 1,744 Phantom Stock Units on 2026-09-25, a grant/compensation rather than a purchase, leaving 205,649 units owned after.
Pfizer director James Quincey received a grant of 1,352 phantom stock units on 2026-09-25, a compensation award rather than a purchase. He held 90,671 such units after the transaction.
Pfizer Inc. director James C. Smith received a grant of 1,570 Phantom Stock Units on 2026-09-25, a compensation award rather than an open-market purchase, bringing his holding to 187,210 units.
Director Cyrus Taraporevala received an award of 1,308 Phantom Stock Units of Pfizer on 2026-09-25, an acquisition via compensation grant, not an open-market purchase. He held 38,806 units after.
Pfizer CEO Albert Bourla received an award of 22 phantom stock units (SSP) at $0.00 on Sept 15, 2026, bringing his reported holdings to 783,985 units. An A-Award is compensation, not an open-market purchase.
Pfizer CEO Albert Bourla received a grant of 21 phantom stock units on 2026-08-31, with no cash involved, increasing his holdings to 784,012.
Pfizer officer Cecile Guegan filed an initial Form 3 disclosing 149,505 common shares and 10 stock appreciation rights holdings (strike prices $25.75-$45.96). No transaction types or share amounts were stated in the rows.
Pfizer CEO Albert Bourla received a grant of 22 phantom stock units on August 14, 2026. He now holds 785,060 phantom stock units.
Filings
61 · Latest SEC filingsPfizer CEO Albert Bourla received an award of 21 Phantom Stock Units SSP at $0.00, bringing his reported holdings to 795,823 units.
Pfizer CEO Albert Bourla received an award of 20 Phantom Stock Units SSP at $0.00 on Oct 30, 2026, as reported in a Form 4 filing. He held 783,828 units afterward.
Pfizer CEO Albert Bourla received an award of 20 phantom stock units (SSP) on 2026-10-15, at $0.00, bringing his reported holdings to 783,997 units. Form 4 filed 2026-10-16.
Pfizer director and Chairman & CEO Albert Bourla received an award of 71 Phantom Stock Units SSP on 2026-10-13, a grant of compensation, bringing reported holdings to 783,981.
Pfizer CEO Albert Bourla reported a Form 4 award of 21 Phantom Stock Units (SSP) at $0.00, an A-Award grant, bringing his reported holdings to 783,888 units.
Pfizer Inc. director Shantanu Narayen received an award of 1,744 Phantom Stock Units on 2026-09-25, a grant/compensation rather than a purchase, leaving 205,649 units owned after.
Director Buckley Mortimer J received an award of 1,308 Phantom Stock Units in Pfizer Inc. on 2026-09-25, at $0.00 per share, bringing holdings to 28,040 units.
Pfizer director Joseph Echevarria received an award of 1,613 phantom stock units at $0.00 on 2026-09-25, bringing his holdings to 169,739 units. This is compensation, not an open-market purchase.
Pfizer director James Quincey received a grant of 1,352 phantom stock units on 2026-09-25, a compensation award rather than a purchase. He held 90,671 such units after the transaction.
Pfizer Inc. director James C. Smith received a grant of 1,570 Phantom Stock Units on 2026-09-25, a compensation award rather than an open-market purchase, bringing his holding to 187,210 units.
Director Cyrus Taraporevala received an award of 1,308 Phantom Stock Units of Pfizer on 2026-09-25, an acquisition via compensation grant, not an open-market purchase. He held 38,806 units after.
Pfizer CEO Albert Bourla received an award of 22 phantom stock units (SSP) at $0.00 on Sept 15, 2026, bringing his reported holdings to 783,985 units. An A-Award is compensation, not an open-market purchase.
Pfizer CEO Albert Bourla received a grant of 21 phantom stock units on 2026-08-31, with no cash involved, increasing his holdings to 784,012.
Pfizer officer Cecile Guegan filed an initial Form 3 disclosing 149,505 common shares and 10 stock appreciation rights holdings (strike prices $25.75-$45.96). No transaction types or share amounts were stated in the rows.
Pfizer CEO Albert Bourla received a grant of 22 phantom stock units on August 14, 2026. He now holds 785,060 phantom stock units.
Albert Bourla, CEO of Pfizer, reported an open-market purchase of 38,000 common shares at $26.34 each, increasing his holdings to 429,173 shares.
Pfizer SVP & Controller Jennifer B. Damico sold 3,278 common shares at $25.40 each on August 5, 2026, reducing her holdings to 28,611 shares.
Director Ronald E. Blaylock purchased 39,231 shares of Pfizer common stock on the open market at $25.46 per share, bringing his total ownership to 66,938 shares.
Director Mortimer J Buckley purchased 37,632 shares of Pfizer common stock on the open market at $25.52 per share, bringing his ownership to 37,632 shares.
Albert Bourla, Chairman & CEO of Pfizer, was awarded 24 Phantom Stock Units (SSP) as compensation on 2026-07-31, bringing his total holdings to 786,154 units. No cash purchase was involved.
Pfizer CEO Albert Bourla was awarded 24 Phantom Stock Units (SSP) on 2026-07-15 as compensation, bringing his total holdings to 772,901 units.
Pfizer Chairman & CEO Albert Bourla was awarded 84 Phantom Stock Units (SSP) on 2026-07-09 as compensation, bringing his total holdings to 772,938 units.
Albert Bourla, Chairman & CEO of Pfizer, received an award grant of 25 Phantom Stock Units SSP on 2026-06-30, a form of compensation, not an open-market purchase. He now owns 772,979 units.
Pfizer director Shantanu Narayen was awarded 2,058 Phantom Stock Units as compensation on 2026-06-26, bringing his total holdings to 200,879 units.
James Quincey, director at Pfizer, was awarded 1,595 Phantom Stock Units as compensation on 2026-06-26, bringing his total holdings to 87,994 units.
Pfizer director Cyrus Taraporevala was awarded 1,544 phantom stock units on 2026-06-26, a form of compensation rather than a purchase, bringing his total holding to 36,941 units.
Director Mortimer J. Buckley was awarded 1,544 Phantom Stock Units at Pfizer on 2026-06-26, a compensation grant rather than a purchase. He now owns 26,335 units directly.
Pfizer director Joseph Echevarria was awarded 1,904 Phantom Stock Units on 2026-06-26 as compensation, bringing his total holdings to 165,632 units.
Pfizer director James C. Smith was awarded 1,853 Phantom Stock Units as compensation on 2026-06-26, bringing his total holdings to 182,886 units.
Albert Bourla, Chairman & CEO of Pfizer, received an award of 23 Phantom Stock Units on 2026-06-15, a form of compensation rather than a purchase. He now owns 772,772 units.
Jennifer B. Damico (SVP & Controller) sold 2,000 shares of Pfizer common stock at $25.70 on 2026-06-09, leaving 31,397 shares owned afterward.
Pfizer CEO Albert Bourla was awarded 23 Phantom Stock Units SSP on 2026-05-29 (not a purchase), bringing his total to 772,789 units.
Pfizer CEO Albert Bourla was awarded 24 Phantom Stock Units (SSP) at $0.00 on 2026-05-15, a form of compensation, bringing his total holdings to 773,297 units.
Pfizer CEO Albert Bourla was awarded 22 Phantom Stock Units SSP on 2026-04-30 as compensation, bringing his total holdings to 760,229 shares.
Pfizer director Dan R. Littman was awarded 7,687 Phantom Stock Units on 2026-04-23, bringing his total holdings to 74,534 units. This was a compensation grant, not an open-market purchase.
This Form 3/A for Dennis P Hancock (EVP) reports no new shares acquired; he holds 1,940 Pfizer common shares as of April 1, 2026.
Pfizer director Shantanu Narayen was granted 7,687 phantom stock units (compensation, not an open-market purchase) on 2026-04-23, bringing his total holdings to 195,612 units.
Director Scott Gottlieb was awarded 7,687 Phantom Stock Units on 2026-04-23 as compensation, bringing his total holdings to 57,002 units.
Pfizer director Suzanne M. Nora Johnson was awarded 7,687 Phantom Stock Units on 2026-04-23 as compensation, bringing her total holding to 116,983 units.
Pfizer director Mortimer J. Buckley was awarded 7,687 Phantom Stock Units on 2026-04-23 as compensation, bringing his total holding to 24,391 units.
Director Susan Desmond-Hellmann received a grant of 7,687 Phantom Stock Units in Pfizer on 2026-04-23, bringing her total holding to 45,636 units. This was a compensation award, not an open-market purchase.
Director Joseph Echevarria was awarded 7,687 Phantom Stock Units on 2026-04-23, bringing his total holdings to 161,085 units. This was a compensation grant, not an open-market purchase.
Director Ronald E. Blaylock received a grant of 7,687 Phantom Stock Units in Pfizer Inc. on 2026-04-23, bringing his total holdings to 84,013 units. This was a compensation award, not an open-market purchase.
Transcripts
Earnings callsFY2026 Q22026-08-04
Earnings calls
AI summary
positivePfizer reported second quarter 2026 revenue of $15 billion, up 1% operationally, and adjusted diluted EPS of $0.77, both ahead of expectations. Excluding COVID products, the underlying business grew 5% operationally, and launched and acquired products delivered $3.2 billion in revenue, up 18% operationally. The company raised its full year 2026 revenue guidance by $500 million at the midpoint to $60.5 billion to $62.5 billion, while lowering its COVID-19 revenue expectation to approximately $4 billion. Adjusted diluted EPS guidance of $2.80 to $3.00 was reaffirmed and absorbs an approximately $0.10 impact from the Innovent Biologics transaction. Pfizer also announced expanded cost-savings programs totaling approximately $9.7 billion in net savings through 2029.
Key takeaways
- Second quarter 2026 revenue was $15 billion, up 1% operationally, and adjusted diluted EPS was $0.77, with revenue excluding COVID products growing 5% operationally.
- Launched and acquired products delivered $3.2 billion in revenue, up 18% operationally, or 27% excluding prior-year one-time items.
- The company now expects approximately $9.7 billion in total net cost savings through 2029, including roughly $2.5 billion in additional savings from 2027 to 2029.
- CEO Albert Bourla stated the company is confident it can maintain its dividend even in the most stretched scenarios, and grow it after the LOE period.
- R&D milestones expected over the next 12 months include 5 regulatory decisions, 8 key readouts and 19 pivotal study starts.
Financial highlights
- Second quarter 2026 revenue was $15 billion, an operational increase of 1% year over year.
- Adjusted diluted EPS was $0.77 in the second quarter, while reported loss per share was $0.04, reflecting $4.3 billion in noncash intangible asset impairments.
- Adjusted gross margin was 76% and adjusted operating margin was 35% in the second quarter, with adjusted operating expenses of $6.1 billion.
- Second quarter operating cash flow was $3.45 billion and leverage ended the quarter at 2.7x.
Guidance
- Full year 2026 revenue guidance was raised by $500 million at the midpoint to a range of $60.5 billion to $62.5 billion.
- Adjusted diluted EPS guidance of $2.80 to $3.00 was reaffirmed, absorbing an approximately $0.10 impact from the $650 million Innovent Biologics acquired in-process R&D charge.
- COVID-19 revenue expectation was revised to approximately $4 billion, down from $5 billion.
- Adjusted gross margin is expected in the mid-70s range, and most of the anticipated $7.2 billion in total net cost savings is expected by the end of 2026.
Q&A themes
- Analysts asked how success would be defined for the mevrometostat MEVPRO-1 prostate cancer readout expected in the fourth quarter.
- Questions focused on drivers of the $1.5 billion non-COVID guidance increase, including Eliquis, and on Padcev growth after its label expansion into muscle invasive bladder cancer.
- Analysts probed obesity strategy for berobenatide and the amylin combination program, including the SOLIS-1 readout expected in 2027.
- Questions covered the atirmociclib adjuvant plan, the Tilrekimig head-to-head trial versus Dupixent, and the long-term COVID franchise trajectory and remaining BD capacity.
Risks
- Lower-than-expected COVID revenues, with low COVID-19 incidence potentially continuing to limit Paxlovid utilization.
- The Phase III overall survival endpoint for SV in second-line non-squamous non-small cell lung cancer was not met, contributing to $4.3 billion in noncash impairments.
- Leverage is expected to remain around current levels or modestly higher through the LOE transition period.
FY2026 Q12026-05-05
Earnings calls
AI summary
positivePfizer reported first-quarter 2026 revenues of $14.5 billion, an operational increase of 2%, and adjusted diluted EPS of $0.75, both above expectations. Excluding COVID products, the underlying business grew approximately 7% operationally, and launched and acquired products delivered $3.1 billion, up about 22% operationally. The company reaffirmed full-year 2026 guidance of $59.5 billion to $62.5 billion in revenues and $2.80 to $3.00 in adjusted diluted EPS. Management cited Vyndamax patent settlements as extending exclusivity to mid-2031 and supporting confidence in a five-year high single-digit revenue CAGR starting in 2029, alongside a Belgian court ruling on Comirnaty EU contracts. Adjusted operating margin was 38%, and leverage ended the quarter at approximately 2.8x.
Key takeaways
- Q1 2026 revenues of $14.5 billion exceeded expectations, up 2% operationally, with approximately 7% operational growth excluding COVID products.
- Launched and acquired products delivered $3.1 billion in Q1, growing approximately 22% operationally, with Seagen products up 20% and Nurtec up 41% operationally.
- Vyndamax settlement agreements delay the related LOE by about 2.5 years on a product with more than $6 billion in revenue, supporting confidence in a five-year high single-digit revenue CAGR starting in 2029.
- Adjusted operating margin was 38% in Q1, and the company remains on track to deliver the majority of $7.2 billion in total net cost savings by the end of 2026.
- Pfizer closed the sale of its ViiV stake in Q2 for approximately $1.65 billion in net proceeds, bringing BD capacity including those proceeds to approximately $7 billion.
Financial highlights
- Q1 2026 revenues were $14.5 billion, an operational increase of 2%, exceeding expectations.
- Q1 2026 reported diluted EPS was $0.47 and adjusted diluted EPS was $0.75, exceeding expectations.
- Adjusted gross margin was approximately 76% in Q1, with higher accrued royalty expense dampening the margin versus the prior-year quarter.
- Q1 operating cash flow was $2.6 billion and leverage ended the quarter at approximately 2.8x.
Guidance
- Full-year 2026 revenues are reaffirmed at $59.5 billion to $62.5 billion.
- Full-year 2026 adjusted diluted EPS is reaffirmed at $2.80 to $3.00 per share.
- Outlook assumes adjusted gross margins in the mid-70s range and that the majority of Comirnaty sales occur toward the end of the year with the vaccination season.
- Leverage is expected to remain around current levels or slightly higher through the LOE transition period.
Q&A themes
- Analysts asked about expected obesity data disclosures at ADA, including VESPER-3, the VESPER-1 open-label extension and VESPER-2, with amylin monotherapy and combination data expected in the second half of 2026.
- Questions focused on 2026 oncology readouts, including SV in second-line lung cancer versus docetaxel expected midyear and MEVPRO-1 in prostate cancer expected in the middle or second half of the year.
- Several questions addressed capital allocation, including the roughly $7 billion BD capacity, the potential for larger transactions, and when share repurchases could return into greater consideration.
- Analysts probed Comirnaty vaccination rates and European contracts in light of the April 1, 2026 Belgian court judgment, which Pfizer is working to implement with Poland and Romania.
Risks
- Pfizer faces LOE headwinds primarily from 2026 through 2028, and leverage is expected to stay around current levels or slightly higher through the transition.
- Sustained low COVID disease levels are expected to continue weighing on Paxlovid utilization over the next several months.
- The company made its final TCJA repatriation tax payment of approximately $2.6 billion in April.
FY2025 Q42026-02-03
Earnings calls
AI summary
positivePfizer reported full year 2025 revenues of $62.6 billion, a 2% operational decline, with 6% operational growth excluding COVID-19 products. Adjusted diluted EPS was $3.22 versus $3.11 last year, ahead of expectations, and the company returned $9.8 billion to shareholders via dividends. Fourth quarter revenues were $17.6 billion, down 3% operationally, driven by an approximate 40% operational decline in COVID products, while non-COVID products grew 9% operationally. Pfizer reaffirmed 2026 guidance of $59.5 billion to $62.5 billion in revenues and $2.80 to $3.00 in adjusted diluted EPS. The call highlighted VESPA-3 results for the ultra-long-acting GLP-1 candidate PF-3944, showing monthly maintenance dosing maintained efficacy and tolerability, with phase three monthly studies planned later this year.
Key takeaways
- Pfizer exceeded 2025 expectations for revenues and adjusted diluted EPS while returning $9.8 billion to shareholders via quarterly dividends.
- Excluding COVID-19 products, operational revenue grew 6% for the full year, and recently launched and acquired products delivered $10.2 billion in revenues, growing approximately 14% operationally.
- The VESPA-3 study met its two main objectives, showing placebo-adjusted weight loss of 10% to 12.3% at week 28 for the low and medium doses planned for phase three and a tolerability profile consistent with weekly GLP-1 receptor agonists when switching to monthly dosing.
- Pfizer plans to advance more than 20 obesity trials, including 10 phase three studies of PF-3944, targeting the first of a series of potential approvals in 2028.
- Fourth quarter GAAP results included approximately $4.4 billion of non-cash intangible asset impairments, including deprioritization of disitamab vedotin in bladder cancer.
Financial highlights
- Full year 2025 revenues were $62.6 billion versus $63.6 billion last year, a 2% operational decline, with 6% operational growth excluding COVID-19 products.
- Full year 2025 adjusted diluted EPS was $3.22 versus $3.11 last year, and reported diluted EPS was $1.36 versus $1.41 last year.
- Fourth quarter revenues were $17.6 billion, down 3% operationally, with non-COVID products growing 9% operationally and COVID products declining approximately 40% operationally.
- Fourth quarter adjusted diluted EPS was $0.66, and adjusted gross margin was approximately 71%, reflecting product mix including lower COVID sales.
Guidance
- Full year 2026 revenues are expected in the range of $59.5 billion to $62.5 billion, unchanged from prior guidance.
- Full year 2026 adjusted diluted EPS is expected in the range of $2.80 to $3.00 per share.
- COVID products are expected to trend lower again in 2026 with revenues of approximately $5 billion, and approximately $1.5 billion in revenue compression is expected from products impacted by anticipated generic entry in 2026.
- Revenues at the midpoint, excluding COVID and LOE products, are expected to grow approximately 4% operationally year over year.
Q&A themes
- Analysts probed VESPA-3 tolerability details, including gastrointestinal adverse events and the absence of down titration in the study, with full data expected at ADA in June.
- Questions focused on phase three obesity trial design, including higher dosing, titration flexibility, and plans for a switching study from weekly to monthly dosing.
- Several questions addressed the ultra-long-acting amylin analog PF-3945, its monotherapy data, and expected combination data with PF-3944 later this year.
- Analysts asked about oncology catalysts, including the integrin beta-6 ADC and the PD-1 VEGF bispecific 4404, and about capital allocation including the dividend and business development capacity.
Risks
- Pfizer faces an LOE cycle from 2026 through 2028, and leverage is expected to remain at current levels or slightly higher through the LOE period.
- COVID product revenues are expected to decline again in 2026 to approximately $5 billion, and generic entry is expected to compress revenue by approximately $1.5 billion in 2026.
- Fourth quarter GAAP results included approximately $4.4 billion of non-cash intangible asset impairments tied to updated long-range forecasts for certain in-line and pipeline assets.
FY2025 Q32025-11-04
Earnings calls
AI summary
positivePfizer delivered Q3 2025 revenues of $16.7 billion (down 7% operationally, driven by COVID products) with adjusted diluted EPS of $0.87, ahead of expectations. The company raised full-year 2025 adjusted EPS guidance by approximately $0.08 to $3.00-$3.15 range, citing strong non-COVID product performance and cost management. Strategic milestones include a U.S. government pricing agreement providing tariff relief and clarity on future innovation investments, FTC early termination of HSR waiting period for Metsera acquisition (expected to close after November 13 shareholder vote), and the 3SBio licensing deal for the SSGJ-707 cancer immunotherapy program.
Key takeaways
- Q3 adjusted diluted EPS of $0.87 exceeded expectations; raised full-year 2025 guidance to $3.00-$3.15 per share
- Non-COVID products grew 4% operationally; Vyndaqel family achieved 7% growth with strong market leadership; Nurtec grew 22% globally; Padcev grew 13%
- U.S. government agreement removes policy uncertainty on drug pricing and provides 3-year tariff grace period with commitment to increase U.S. manufacturing investment
- Metsera acquisition (~$4.9 billion) expected to close post-November 13 shareholder vote; FTC granted unprecedented early HSR termination during government shutdown
- SSGJ-707 (PD-1 VEGF bispecific) Phase II colorectal cancer data presented at ESMO; additional data expected at SITC meeting; Phase III programs starting in lung and colorectal cancer
Financial highlights
- Q3 2025 revenues: $16.7 billion (down 7% operationally); adjusted gross margin approximately 76%
- Q3 adjusted diluted EPS: $0.87; reported diluted EPS: $0.62 (includes ~$0.20 headwind from 3SBio acquired in-process R&D)
- Full-year 2025 revenue guidance maintained at $61-$64 billion; adjusted R&D guidance refined to $10-$11 billion; effective tax rate expected ~11%
- Year-to-date 2025 operating cash flow: approximately $6.4 billion; gross leverage at Q3: 2.7x (expected above target post-Metsera close)
Guidance
- Full-year 2025 adjusted diluted EPS raised to $3.00-$3.15 (from previous guidance, narrowed by ~$0.08 at midpoint)
- Full-year 2025 revenues maintained at $61-$64 billion with assumed favorable FX impact; COVID products expected to remain soft
- Metsera expected ~$0.16 dilutive to 2026 adjusted EPS; 3SBio expected additional $0.05 dilution in 2026
- 2026 guidance expected to be provided by end of current year; company expects leverage above 2.7x target post-Metsera close, to be reduced over time
Q&A themes
- Metsera acquisition defended as strategically sound; Novo Nordisk offer characterized as illegal antitrust violation attempting to 'catch and kill' competitor; company pursuing all legal remedies
- Vyndaqel facing pricing headwinds from IRA manufacturer rebates and payer contracting but maintaining volume growth and market share leadership despite new competition
- PCV25 adult Phase III start delayed to 2026 pending FDA alignment on study design and endpoints; pediatric fourth dose data expected early 2026
- MFN agreement expected to dilute 2026 results; international pricing pressures noted with company signaling willingness to forgo reimbursement rather than accept unsustainable prices
Risks
- COVID-19 franchise significantly underperforming initial $9 billion full-year expectation; low infection rates and vaccination uptake creating material revenue headwind despite derisked EPS guidance
- Metsera acquisition faces significant execution risk with ongoing legal challenges from competing bidder; even if approved, deal expected dilutive through 2030 and dependent on successful pipeline progression
- MFN pricing agreement expected to pressure 2026 financial results; sustainability of international pricing model uncertain with company indicating willingness to exit markets if reimbursement inadequate
FY2025 Q22025-08-05
Earnings calls
AI summary
positivePfizer delivered strong Q2 2025 results with 10% operational revenue growth to $14.7B and adjusted EPS of $0.78, driven by oncology momentum (Padcev +38%, LORBRENA +48%), cardiovascular strength (Vyndaqel +21%), and commercial execution. The company raised full-year EPS guidance despite quantifying but not disclosing potential impacts from MFN and tariff policy discussions with the administration. Management emphasized robust R&D pipeline progress including Elrexfio expansion opportunities, Sigvotatug Vedotin lung cancer studies, and the 3SBio PD-1/VEGF licensing deal.
Key takeaways
- Q2 revenues grew 10% operationally to $14.7B; adjusted EPS of $0.78 exceeded expectations on strong portfolio performance and cost discipline
- Raised full-year 2025 adjusted EPS guidance by $0.10 (excluding $0.20 3SBio charge) to $2.90-$3.10 range, driven by operational strength and improved tax rate of ~13%
- Major pipeline progress: Elrexfio showing >97% response rate in newly diagnosed multiple myeloma (MagnetisMM-6); SV vedotin Phase III fully enrolled in lung cancer with 31% response rate in second-line
- Commercial momentum across oncology (Padcev, LORBRENA, Braftovi/Mektovi), cardiovascular (Vyndaqel international +32%), and hematology (Hympavzi Phase III met endpoint with 93% bleeding reduction)
- Lowered leverage target from 3.25x to 2.7x; $13B remaining BD capacity after 3SBio deal; expects $7.7B cumulative cost savings by end 2027
Financial highlights
- Q2 2025 revenues $14.7B (+10% operationally); adjusted diluted EPS $0.78 vs. expectations
- Adjusted gross margin ~76%; operating expenses down 8% operationally with R&D down 9% and SG&A down 8%
- Full-year 2025 revenue guidance maintained at $61-64B; adjusted EPS guidance raised to $2.90-$3.10 (from prior $2.80-$3.00)
- H1 2025 operating cash flow $1.8B; leverage at 2.7x (down from 3.25x target); on track for $4.5B+ cumulative cost savings by year-end 2025
Guidance
- Full-year 2025 revenues: $61-64B (unchanged); adjusted diluted EPS: $2.90-$3.10 (+$0.10 vs. prior guidance)
- Adjusted SG&A: $13.1-14.1B; adjusted R&D: $10.4-11.4B; adjusted effective tax rate: ~13%
- Guidance absorbs currently imposed tariffs from China, Canada, Mexico and quantified MFN impact from President Trump's July 31 letter; COVID revenues forecasted primarily in Q3-Q4
- Expects improved H2 2025 cash flows and continued deleveraging toward 2.7x leverage target; Phase I manufacturing optimization expected to deliver $1.5B savings by end 2027
Q&A themes
- MFN and tariff policy: Management in 'extremely productive' discussions with administration; quantified potential impacts in guidance but declined to disclose specific numbers; also negotiating PBM reform, 340B abuse, and pill parity issues
- BD strategy: Maintaining smaller deal approach with $13B capacity after 3SBio; will exceed 2.7x leverage if compelling opportunity arises (like Seagen); prioritizing oncology, vaccines, cardiometabolic/obesity, and immunology
- Vyndaqel dynamics: U.S. growth pressured by Medicare Part D redesign and contracting for access maintenance (90% access retained), but international growing 32% with only 50% patient penetration vs. U.S.; continued volume growth expected despite GTM pressure
- Seagen integration: Portfolio growing 15% YoY; four main assets (Padcev, SV, PDL1V, TOPO1 payloads) projected to grow from ~$2B to ~$10B by 2030; confidence in positive IRR on $42B acquisition through platform value and IP
Risks
- Policy uncertainty: MFN pricing pressure and potential tariff impacts quantified in guidance but subject to ongoing administration negotiations with undefined outcomes; multiple scenarios modeled but probabilities undisclosed
- COVID revenue volatility: Guidance intentionally derisked for Q3-Q4 COVID performance despite internal confidence in achieving targets; business noted as 'more fluid and harder to predict quarter-over-quarter'
- Competitive pressures: Vyndaqel facing share losses to Attruby in first-line; ADCETRIS and TUKYSA experiencing headwinds; Nurtec pressured by IRA Medicare Part D redesign and 340B program impact despite 47% market share
FY2025 Q12025-04-29
Earnings calls
Company news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.- Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development
- Pfizer secures up to $1.5 billion from Blackstone for obesity drug development
- Pfizer Raises Forecast on Momentum With New Products
- Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis
- Pfizer to cut around 330 jobs in Italy
- Florida Attorney General sues Pfizer and CEO over COVID-19 vaccine claims
- Pfizer CEO Bourla plans to attend White House state dinner for China's Xi, source says
- Pfizer Makes an Unusual Enemy in $2 Billion Fight Over Unwanted Covid-19 Vaccines
- US FDA approves updated COVID vaccines for 2026-27 season
Company data
Company intelligence
Updated: Nov 22, 2026, 08:31 AM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Chief executive
- Albert Bourla
- Employees
- 75,000
- IPO date
- Jun 1, 1972
- Country
- US
- Exchange
- New York Stock Exchange
Rating factors
- Return on equityi
- 3/5
- Return on assetsi
- 4/5
- Debt to equityi
- 1/5
- Price to earningsi
- 1/5
- Price to booki
- 3/5
Company press releases
Congressional disclosures
Senate
House
Market cap history
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| VOO | 0.27% | 151.5M |
| VTS.AX | 0.24% | 142.8M |
| VTI | 0.24% | 142.8M |
| 1655.T | 0.25% | 76.6M |
| 1657.T | 0.19% | 76.6M |
| XAW.TO | 0.15% | 76.6M |
| IVV | 0.25% | 76.5M |
| FXAIX | 0.25% | 73.1M |
| SPY | 0.25% | 69.9M |
| VTV | 0.63% | 54.8M |
| XLV | 2.4% | 42.1M |
| VIIIX | 0.27% | 30M |
Analyst track record
How the analysts covering PFE have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 205 | 582 |
| Analysts | 31 | 41 |
| Buy / hold / sell | 64 / 130 / 11 | 181 / 388 / 13 |
| Upgrades / downgrades / initiations | 4 / 3 / 3 | 6 / 7 / 9 |
| Price targets hit / missed | 72 / 114 (39%) | 125 / 389 (24%) |
| Avg. return after a rating (TipRanks) | -3.8% | -7.4% |
| Best / worst call | +10.2% / -23.5% | +19.7% / -76.1% |
After buy calls on this stock: median 21-day move -0.2% vs S&P 500 -1.8% (n = 187)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Evan SeigermanBMO Capital8% hit rate on this stock · 25 targets measuredBuytarget $35.00Nov 4, 2026
- Louise ChenScotiabank7% hit rate on this stock · 14 targets measuredBuytarget $35.00Nov 4, 2026
- Akash TewariJefferies0% hit rate on this stock · 28 targets measuredBuytarget $36.00Nov 3, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 16, 2026 | Emily FieldBarclaysNov 16, 2026 | SellMaintained | $25.00↗ | article ↗ |
| Nov 16, 2026 | Unknown AnalystLeerink PartnersNov 16, 2026 | HoldMaintained | – | |
| Nov 6, 2026 | Ilya ZubkovFreedom Capital MarketsNov 6, 2026 | BuyMaintained | $34.00↗ | article ↗ |
| Nov 5, 2026 | Elmar KrausDZ BANK AGNov 5, 2026 | HoldDowngraded | –↗ | article ↗ |
| Nov 4, 2026 | Vamil DivanGuggenheimNov 4, 2026 | BuyMaintained | $33.00↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 20, 2026 · 205 ratings
Frequently asked questions
Where can I trade PFE perpetual futures?
Pfizer Inc. (PFE) perpetual futures trade on 15 crypto venues, including Ourbit, LBank, XT.com. PerpEquities compares them by live price, funding rate, open interest and liquidity.
Can I trade PFE around the clock?
Yes. Unlike the underlying stock, PFE perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on PFE perpetuals?
Right now the PFE perp funding rate is 0.0% annualized (venue median), ranging from -24.1% to 0.0% across 15 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.
How does the PFE perp price compare to the Pfizer Inc. stock?
The venue-median PFE perp mark is $27.5 versus a reference stock price of $27.5, a basis of -0.1%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a PFE perpetual future?
A PFE perpetual is a derivative that tracks the price of Pfizer Inc. with no expiry date. It lets you take long or short exposure to Pfizer Inc. on crypto venues, around the clock.
What is PFEUSDT perpetual?
PFEUSDT is the symbol most crypto exchanges use for the Pfizer Inc. perpetual settled in USDT (Tether). It tracks the PFE share price through an index, trades 24/7 with leverage and never expires.
Ourbit
XT.com
KuCoin
Binance
BingX
Variational
MEXC
Bitunix
HTX
Bitget
OKX
Bybit
Helix (Injective)
Gate.io
LBank